Genetic Test Scores Predicting Intelligence Are Not the New Eugenics

Genetic Test Scores Predicting Intelligence Are Not the New Eugenics

A thinking person.

(© psdesign1/Fotolia)


Keep Reading Keep Reading
Paige Harden
Dr. Paige Harden is tenured professor of clinical psychology at the University of Texas at Austin, where she is the Principal Investigator of the Developmental Behavior Genetics lab and co-director of the Texas Twin Project. Dr. Harden has published over 100 scientific articles on genetic influences on complex human behavior, including child cognitive development, academic achievement, risk-taking, mental health, sexual activity, and childbearing. In 2017, she was honored with a prestigious national award from the American Psychological Association for her distinguished scientific contributions to the study of genetics and human individual differences. Dr. Harden’s research is supported by a Jacobs Foundation Early Career Research Fellowship, the Templeton Foundation, and the National Institutes of Health. She is a Public Voices Fellow with the Op-Ed Project.
Hidden figures: Five black women that changed science forever

Dr. May Edward Chinn, Kizzmekia Corbett, PhD., and Alice Ball, among others, have been behind some of the most important scientific work of the last century.


Keep Reading Keep Reading
Sarah Watts

Sarah Watts is a health and science writer based in Chicago.

natural killer cell
NIAID, CC BY 2.0 <https://creativecommons.org/licenses/by/2.0>, via Wikimedia Commons

On today’s episode of Making Sense of Science, I’m honored to be joined by Dr. Paul Song, a physician, oncologist, progressive activist and biotech chief medical officer. Through his company, NKGen Biotech, Dr. Song is leveraging the power of patients’ own immune systems by supercharging the body’s natural killer cells to make new treatments for Alzheimer’s and cancer.

Whereas other treatments for Alzheimer’s focus directly on reducing the build-up of proteins in the brain such as amyloid and tau in patients will mild cognitive impairment, NKGen is seeking to help patients that much of the rest of the medical community has written off as hopeless cases, those with late stage Alzheimer’s. And in small studies, NKGen has shown remarkable results, even improvement in the symptoms of people with these very progressed forms of Alzheimer’s, above and beyond slowing down the disease.

Keep Reading Keep Reading
Matt Fuchs
Matt Fuchs is the host of the Making Sense of Science podcast and served previously as the editor-in-chief of Leaps.org. He writes as a contributor to the Washington Post, and his articles have also appeared in the New York Times, WIRED, Nautilus Magazine, Fortune Magazine and TIME Magazine. Follow him @fuchswriter.